Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced the presentation of additional clinical data from its Phase 1 clinical trial of KER-065 at the American Society of Bone and Mineral Research 2025 Annual Meeting. The study involved healthy male volunteers and focused on the safety, tolerability, and pharmacokinetics of KER-065, a modified activin receptor ligand trap. The results, as of the data cut-off date of April 29, 2025, indicated that the treatment was generally well-tolerated across all dose levels, with no serious adverse events reported. A single grade 4 treatment-emergent adverse event was observed but was deemed unrelated to the treatment. Most adverse events were mild to moderate and resolved. The trial demonstrated changes in bone biomarkers, indicating increased bone formation and reduced bone resorption, with observed increases in bone mineral density. These findings support the potential development of KER-065 for treating Duchenne muscular dystrophy and other bone disorders.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001664710-25-000081), on September 08, 2025, and is solely responsible for the information contained therein.
Comments